Commercial Genomic Assays for Localized Prostate Cancer: How Do They Compare?

Tissue-based genomic assays vary in their validation data to predict long and short-term outcomes. They also differ in the ability of their results to help guide the active surveillance decision in low- and favorable intermediate-risk patients.

To learn about the similarities and differences in how these assays were validated for their reported results, watch the webinar now.

Commercial Genomic Assays for Localized Prostate Cancer: How Do They Compare?

Featured Speakers:

Andrew Stephenson, MD Andrew Stephenson, MD
“Oncotype® has done the heavy lifting to validate this test for exactly what you want: a biopsy test in a candidate for Active Surveillance, and you want to determine the aggressiveness of their cancer”

“Not all of them are consistent in how they stratify and in their validation”

Neal D. Shore, MD, FACS Dr. Neal Shore, MD, FACS


The only assay designed for critical treatment decisions in clinically low-risk, early-stage prostate cancer

Comparison of prostate biopsy genomic tests

  Oncotype DX GPS assay Prolaris® Test Decipher® Prostate Biopsy Test
Genes selected based on their performance in prostate cancer in the biopsy setting1-4 checkmark
Extensive clinical validation across large cohorts of GS 3+3 and 3+4 patients who are eligible for active surveillance1,4-20 checkmark
Optimized and analytically validated for small prostate biopsy tissue samples2,10,19 checkmark
5 ng of RNA
200 ng of RNA 25-100 ng of RNA

Validated endpoints in a biopsy setting:

Oncotype DX GPS assay
Prolaris® Test
Decipher® Prostate Biopsy Test
  • Metastasis after RP13
  • PCM after RP13
  • AP (Gleason grade ≥ 4+3 and/or pT3+)13*
  • BCR7,13
  • Metastasis after RP20
  • PCM after conservative management (watchful waiting)15,16
  • BCR20
  • Metastasis after RP3
  • PCM after RP3
  • AP (Gleason ≥ 4+3 and pT3b+ only)17*
  • RP = radical prostatectomy; BCR = biochemical recurrence; PCM = prostate cancer mortality
    *Prospective validation data for this clinical endpoint.21

    Choose the Oncotype DX GPS assay to drive immediate and actionable treatment decisions.


    * Adverse Pathology is defined as high-grade and/or non-organ-confined disease.

    1. Klein et al. Eur Urol. 2014.
    2. Cuzick et al. Lancet Oncol. 2011.
    3. Nguyen et al. Eur Urol. 2017.
    4. Erho et al. PLoS ONE. 2013.
    5. Badani et al. Urol Pract. 2015.
    6. Bonham et al. USCAP. 2016.
    7. Cullen et al. Eur Urol. 2015.
    8. Dall’Era et al. Urol Pract. 2015.
    9. Eggener et al. Urology. 2019.
    10. Knezevic et al. BMC Genomics. 2013.
    11. Lynch et al. Am J Manag Care. 2018.
    12. Salmasi et al. J Urol. 2018.
    13. Van Den Eeden et al. Eur Urol. 2017.
    14. Eure et al. Urology. 2017.
    15. Eure et al. AUA. 2017.
    16. Cuzick et al. Br J Cancer. 2015.
    17. Cuzick et al. Br J Cancer. 2012.
    18. Kim et al. Prostate Cancer Prostatic Dis. 2018.
    19. Albala et al. Rev Urol. 2016.
    20. Klein et al. Urol. 2016.
    21. Bishoff et al. J Urol. 2014.
    Making cancer care smarter.™

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.